JAK1 and acquired polycythemia vera: Ruxolitinib, an orally bioavailable inhibitor of JAK1 and JAK2, is currently the only pharmacotherapy with approved indications in MF, and it has been recently approved by the US Food and Drug Administration for the treatment of patients with PV with an inadequate response to or intolerant of hydroxyurea.